Skip to main content

Advertisement

Table 1 Patient characteristics

From: Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01)

  TAC + ZA
N = 122 (49.6%)
TAC
N = 124 (50.4%)
IGF-1R biopsy data available
N = 188 (76.4%)
Serum data available
N = 37
(15%)
Median age (range), Years 48.0 (29–67) 49.0 (34–70) 49 (29–70) 49 (34–65)
Median BMI (range), kg/m2 26.1 (18.5–40.0) 25.0 (18.3–42.0) 25.0 (18.3–42.0) 24.9 (19.4–39.5)
Menopausal status
 Pre/peri 72 (59.0%) 75 (60.5%) 110 (58.5%) 24 (64.9%)
 Post 50 (41.0%) 47 (37.9%) 76 (40.4%) 13 (35.1%)
T-classification
 T1/T2 73 (59.8%) 71 (57.3%) 108 (57.4%) 21 (56.8%)
 T3/T4 49 (40.2%) 53 (42.7%) 80 (42.6%) 16 (43.2%)
N-classification
 N0 54 (44.3%) 56 (45.2%) 90 (47.9%) 22 (59.5%)
 N+ 68 (55.7%) 68 (54.8%) 98 (52.1%) 15 (40.5%)
HR-status
 ER+ and/or PR+ 101 (82.8%) 104 (83.9%) 158 (84.0%) 33 (89.2%)
 ER− and PR− 21 (17.2%) 20 (16.1%) 30 (16.0%) 4 (10.8%)
  1. TAC docetaxel, doxorubicin and cyclophosphamide, ZA zoledronic acid, BMI body mass index, HR hormone receptor, ER estrogen receptor, PR progesterone receptor, pCR pathologic complete response, LN lymph nodes, MP Miller and Payne